Pegargiminase for non-alcoholic fatty liver disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 May 2023: Trial registered, NCT05842512
  2. 13 Sep 2023: Trial started, NCT05842512

The trials

NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

State
Under way
Phase
Phase 2
People
60 planned
Started
13 Sep 2023
Primary completion
31 Dec 2027
Arms
Drug: ADI-PEG 20
Results
None posted
  1. 6 May 2023: Trial registered
  2. 13 Sep 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.